<DOC>
	<DOCNO>NCT02477449</DOCNO>
	<brief_summary>Phase 1 study investigate safety istaroxime healthy chinese volunteer .</brief_summary>
	<brief_title>Istaroxime Infusion 24 Hours Chinese Healthy Volunteers</brief_title>
	<detailed_description>32 subject ( F : M=1:1 ) randomize three dose group ( 0.25-0.5-1.0ug/kg/min ) . 8 subject 0.25ug/kg/min group administrate Istaroxime + 0.9 % NS ; 12 subject 0.5ug/kg/min 1.0 ug/kg/min group randomly receive Istaroxime placebo + 0.9 % NS ( 2 subject ) , 0.9 % NS alone ( 2 subject ) Istaroxime + 0.9 % NS ( 8 subject ) . All subject give infusion study drug 24 hour , observe 48 hour clinic . At least 1 week keep two dose group . Escalation high dose occur low dose group complete significant safety issue find .</detailed_description>
	<criteria>1 . Age 1845 year ( inclusive ) 2 . Male Nonpregnant , nonlactating woman 3 . Chinese healthy subject 4 . Body mass index ( BMI ) 1924 kg/m2 ( inclusive ) body weight 50100kg 5 . Lab examination ( include limit : Hemoglobin , white blood cell counting , differential count , creatinine , Alkaline phosphatase ( ALP ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , Total bilirubin urinalysis ) within normal range normal range clinical significance . 6 . Vital sign screen phase : SBP100139mmHg , DBP 5089 mmHg , pulse rate 4590 bpm . Holter within normal range normal range clinical significance . 7 . Both physical examination ECG baseline normal abnormal clinical significance 8 . Women childbearing age trial must willing use medically acceptable method contraception , include surgical sterilization ( tubal ligation / hysterectomy ) , double barrier method hormonal contraception . 9 . Subjects well communicate investigator , understanding requirement investigator willing sign ICF conducting studyrelated procedure . 10 . Subjects willing stay phase I ward throughout study . 1 . Disease history liver , kidney , endocrine , cardiovascular , neurological , psychiatric , gastrointestinal tract , lung , immune , skin , blood , metabolic disorder cancer , may great impact study result . 2 . Presence pancreatitis , intestinal obstruction , glaucoma , prostatic hypertrophy , adrenal disease , hyperthyroidism gallbladder disease ( subject experience cholecystectomy exclude ) 3 . History clinical significant disease past 4 week screen visit 4 . Presence disease know disturb absorption , distribution , metabolism excretion Istaroxime 5 . Physical examination , medical history , ECG , vital sign lab examination deem abnormal clinical significant 6 . Be intolerant allergy Istaroxime , lactose similar substance 7 . Significantly abnormal diet conduct within 4 week screen visit 8 . Blood donation loss equal exceed 400ml past 6 month 9 . Participating drug study past 3 month 10 . Administrated OTC drug include vitamin supplement herbal ( Occasional use paracetamol exclude ) 11 . Regular use prescription drug ( Hormonal birth control pills hormone replacement therapy exclude ) 12 . Drinking beverage eat food contain caffeinated / xanthine poppy seed since 48 hour study drug administration ; drink beverage eat food contain grapefruit , oranges Chinese tea 14 day study drug administration 13 . Receiving therapy drug include cytochrome P450 3A4 cytochrome P450 2C8 inhibitor inducer ( eg barbiturate , carbamazepine , erythromycin , phenytoin , thiazoline TZDs , Rifampin ) 14 . Women Lactation period positive pregnancy test 15 . Tongue pierce lip piercing occur 30 day study drug administration 16 . Smoke tobacco use 60 day study drug administration 17 . History abuse substance include infusion drug , alcohol opium 18 . Positive alcohol breathe test within 1day drink alcohol within 1week 19 . Abusing drug ( include Opioids , oxycodone , methamphetamine , amphetamine , cannabinoids , cocaine , barbiturate , benzodiazepine class , methadone , buprenorphine phencyclidine ) 20 . History heart disease 21 . Planning pregnant recent 3 month 22 . Participating interventional strudy past 30 day 23 . History bronchial asthma blood porphyria disease 24 . HbsAg , antiHCV , antiHIV anti syphilis positive 25 . Holter examination abnormal clinical significant 26 . Subjects eligible study judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>safety</keyword>
	<keyword>istaroxime</keyword>
</DOC>